GlassScriptPhysician profile
Sunil Upadhaya
NPI 1356724553
$6,521.73
in general payments reported to CMS, 2019-2025
23 companies · $3,747 in 2025
The $3,747 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $118 · 2022: $709 · 2023: $730 · 2024: $1,217 · 2025: $3,747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,058 · Grant: $2,000 · Education: $636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,058.14 |
| Grant | $2,000.00 |
| Education | $636.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,435.30 | 2025 | Symplicity G3, Resolute Onyx |
| Abbott Laboratories | $1,074.78 | 2022-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Merlin@Home, Coroflow |
| Abiomed | $438.66 | 2023-2025 | Impella |
| Boston Scientific Corporation | $375.64 | 2024-2025 | General - Balloon Catheters, General - Vascular Access |
| Angiodynamics, INC. | $355.21 | 2022-2025 | Alphavac, Auryon Laser System 100-120 Vac |
| Inari Medical, INC. | $269.95 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Astrazeneca Pharmaceuticals LP | $235.06 | 2023 | Farxiga, Brilinta |
| Edwards Lifesciences Corporation | $189.79 | 2025 | Sapien 3 Ultra Resilia |
| Shockwave Medical, INC | $185.99 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Penumbra, INC. | $141.22 | 2024 | Indigo System |
| Pfizer INC. | $100.00 | 2022 | |
| Viiv Healthcare Company | $99.99 | 2021 | |
| Stryker Corporation | $98.10 | 2025 | Flowtriever, Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.35 | 2023 | Jardiance |
| Chiesi USA, INC. | $70.29 | 2024 | Kengreal |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $66.36 | 2024-2025 | Camzyos |
| Amgen INC. | $66.03 | 2023-2024 | Repatha |
| Biotronik INC. | $59.45 | 2022-2024 | Renamic Neo |
| Janssen Pharmaceuticals, INC | $42.02 | 2024 | Xarelto |
| Atricure, INC. | $40.73 | 2023 | |
| Merck Sharp & Dohme LLC | $34.60 | 2021-2024 | Verquvo |
| Novo Nordisk INC | $24.73 | 2024 | |
| Esperion Therapeutics, INC. | $21.48 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Upadhaya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.